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Objectives. To review the natural history and biological potential of small renal masses in order to evaluate surveillance as
a treatment option. Methods. Literature search of Medline and additional references from non-Medline-indexed publications
concerning surveillance of small renal masses. Results. The natural history and biological potential of small renal masses can still
not be unambiguously predicted at present. There seems to be no clear correlation between tumour size and presence of benign
histology. The majority of small renal masses grow and the majority are cancer, but one cannot safely assume that a lack of growth
on serial CT scans is the conﬁrmation of absence of malignancy. Needle core biopsies could be used to help in decision making.
They show a high accuracy for histopathological tumour type but are less accurate in evaluating Fuhrman grade. Conclusions.
At present, surveillance of small renal masses should only be considered in elderly and/or inﬁrm patients with competing health
risks, in those with a limited life expectancy, and in those for whom minimal invasive treatment or surgery is not an option. In all
other patients, active surveillance should only be considered in the context of a study protocol. Long-term, prospective studies are
needed to provide a more accurate assessment of the natural history and metastastic potential of small renal masses.
Copyright © 2008 S. Klaver et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The increased use of modern imaging techniques has lead
to an increase in incidentally detected small renal tumours,
leading to an increase of asymptomatic small renal masses
withnoevidenceofmetastaticdisease.Thegreatestincidence
of these tumours occurs in patients older than 70 years
in whom multiple comorbidities may increase the risks of
surgery [1].
The accepted standard treatment for the last 50 years
for clinically localised renal cell carcinoma (RCC) has
been radical nephrectomy; however, more recently nephron-
sparing surgery has become the gold standard for most small
renal masses.
There is an increased interest in minimally invasive
therapies nowadays, such as radiofrequency ablation and
cryotherapy, with encouraging short-term data. However,
long-term outcome data are still awaited. Despite the
decreased perioperative morbidity of partial nephrectomy
with advances in surgical techniques, especially the laparo-
scopic approach, some patients may not be candidates
for surgery because of medical comorbidities [2–4]o r
unwillingness to undergo surgical resection.
Previous ﬁndings assume that many small renal masses
have a slow growth rate and a low metastatic potential.
This has raised the question of close monitoring as an
alternative to surgery. To be able to implement such strategy,
a better understanding of the biological behaviour and
naturalhistoryoftheselesionsisimportant. Wereviewedthe
available data from two prospective studies [5, 6] and several
small case series [7–17] describing the short-term outcomes
of expectantly followed renal masses to better assess the
current role of active surveillance as a therapeutic strategy
of these small renal masses.
2. SMALL RENAL MASSES AND THEIR
NATURAL HISTORY
Kouba et al. [1] suggested that active surveillance for
renal masses is an appropriate option in selected patients,
especially those with competing comorbidities, since delayed2 Advances in Urology
intervention after an initial period of surveillance does not
appear to adversely impact pathological outcomes. They
published the results of a retrospective case series including
43 patients with 46 renal masses (24% of tumours >4cm)
who underwent active surveillance of enhancing solid or
cystic Bosniak IV renal masses. A subset of 13 patients
who ultimately underwent surgical intervention was also
examined. Mean delay to intervention was 12 months. At
a 36 months mean follow-up, renal masses grew in 74% of
patients with a mean (median) growth rate of 0.70 (0.35)cm
per year, no patient died of RCC and none had evidence of
metastatic disease. Initial tumour size (3.1 versus 2.6cm, p =
0.4504) was similar in the intervention and nonintervention
groups and growth rate did not correlate with initial tumour
size.
Volpeetal.[5]reportedintheirreportthatonlyonethird
of small renal masses grew during surveillance and therefore
raising the possibility of a period of initial observation in
selectedpatients,especiallyininﬁrmorelderlypatients.They
prospectively followed 29 patients with 32 small renal masses
(<4cm, 7 lesions were complex cystic masses) for a median
of27.9monthswhorefusedorweredeemedunﬁtforsurgical
treatment. The median baseline volume was 4.9cm3 for the
25 solid masses and 22.8cm3 for the 7 cystic masses. The
average growth rates for the solid and the cystic masses were
comparable (0.11 and 0.09cm per year, resp.; P = .41).
Also Rendon et al. [6], who prospectively followed 13
patients with small renal masses for a median of 42 months,
concluded that most small renal masses grow slowly, if at
all, and metastases are unlikely to arise before the mass
shows rapid growth. Later, in 2006 Rendon and Jewett [18]
reviewed the available data on the natural history of small
renal masses and considered surveillance a feasible and safe
option in patients with a short-life expectancy or within
a well-controlled clinical trial. They recommended close
imaging follow-up should be performed every 3 months for
the 1st year, every 6 months for the next 2 years, and every
year thereafter. A cut-oﬀ tumour size of 4cm was considered
safe although this has not yet been systematically validated.
Most other published series concerning this matter are
small retrospective case series with limited follow-up and
pathology data for many patients are missing [7–15]. The
individual investigators advise that a period of surveillance
can be safely performed in patients who are medically unﬁt
for surgery.
Chawla et al. [16] performed a meta-analysis in which
they combined the data from several small observational
series and their institutional series, including 234 untreated
localised small renal masses with a mean follow-up of 34
months [5–15]. This analysis revealed ﬁrst of all that the
majority of the lesions with a mean size of 2.60cm have a
slow growth rate (mean rate 0.28cm per year) and rarely
metastasise and this in only 1% of cases while under active
monitoring. Secondly, the initial tumour size did not predict
the overall growth rate (P = .46). An absolute safe cut-oﬀ
for surveillance may therefore not exist since the metastatic
potential of observed tumours cannot be predicted. Only
46%ofthepatientshadpathologicalevaluationhoweverand
the pathologically analysis was incomplete in many cases.
3. NATURE OF SMALL RENAL MASSES IN
RELATION TO TUMOUR SIZE
3.1. Benignlesions
A signiﬁcant number of renal masses are actually benign
tumours. It remains diﬃcult to diﬀerentiate oncocytomas,
forinstance,fromrenalcellcarcinomas(RCCs)andthiseven
with the most advanced cross-sectional imaging techniques.
In a literature review by Chawla et al. [16] including 76
tumours (12% oncocytomas, 88% RCCs), there was no
statistical diﬀerence in mean initial tumour size (2 versus
2.2cm) or mean growth rate (0.16 versus 0.35cm per year)
comparing oncocytomas versus RCCs, respectively [16, 17].
Radiographic data alone are yet still unable to predict the
exact natural history of small renal masses. A retrospective
study by Remzi et al. [19] reported that 81.9% of all small
renal masses were RCC and only 17% were correctly deﬁned
a sb e n i g no np r e o p e r a t i v eC T .
Although up to 90% of the solid renal masses are RCCs,
elderly patients with small renal masses are up to 3.5 times
more likely to have benign lesions than RCCs [18]. Recent
data suggest that smaller lesions may have an even greater
chance of being benign than previously recognised [20–22].
As the tumour size increases, there is a signiﬁcantly greater
probability that the tumour is malignant versus benign, clear
cell versus papillary RCC, and high-grade versus low-grade
RCC. These results provide a pathological basis for the use of
surveillance strategies in the treatment of small renal masses
in poor surgical candidates. In the EORTC 30904 study by
Van Poppel et al. [21], 11.6% of the 541 surgically removed
tumours (≤5cm) were benign. In another study by Gill et
al. [22], 30% of the 100 tumours treated with laparoscopic
partial nephrectomy were benign. The tumours had a mean
diameter of 2.8cm.
Schlomer et al. [23] examined the relationship between
tumour size and pathological ﬁndings in 349 renal masses
(Table 1). The percent of malignant tumours increased from
72.1% for those <2cm in diameter to 93.7% for those
>7cm (odds ratio = 1.39; 95% conﬁdence interval, 1.17–
1.65). Lesions ≤4cmand>7cm were associated with high-
F u h r m a ng r a d e( G 3 / G 4 )i nf e w e rt h a n2 8 %a n di ng r e a t e r
than 63% of the cases, respectively (chi-square test P<. 001).
Small renal tumours are more likely to be benign or to be of
lower grade than larger tumours.
It seems to be that small renal masses might be benign
and that larger renal masses are RCC. Tumour size alone
however does not provide adequate information for deciding
on the optimal treatment. Preoperative evaluation should be
more reﬁned.
3.2. Smallrenaltumours:howbenignarethey?
Remzi et al. [24] reviewed data of 287 small renal masses
(≤4cm) detected by CT and treated surgically with patho-
logical analysis. They found no correlation between tumour
size and benign histology. In this analysis, tumours were
stratiﬁed according to preoperative diameter into three or
two groups (Table 2). What they found is that FuhrmanS. Klaver et al. 3
Table 1: Tumour size versus histology [23].
Tumour size (cm) No. of benign tumours (%) No. of RCC (%)
0.0–0.9 (n = 7) 1 (14.3) 6 (85.7)
1.0–1.9 (n = 54) 16 (29.6) 38 (70.4)
2.0–2.9 (n = 83) 19 (22.9) 63 (75.9)
3.0–3.9 (n = 63) 11 (17.5) 52 (82.5)
4.0–4.9 (n = 32) 3 (9.4) 28 (87.5)
5.0–5.9 (n = 29) 2 (6.9) 26 (89.7)
6.0–6.9 (n = 18) 0 (0.0) 18 (100.0)
7.0 or greater 4 (6.3) 58 (92.1)
Totals 56 (16.0) 289 (82.8)
grades G3 and G4, higher pathological stage (pT3a or
greater), and metastatic disease were seen signiﬁcantly more
frequently in tumours >3cm in diameter. This diﬀerence
was however not observed when masses ≤2cm in diameter
were compared with those measuring 2.1–3.0cm. Taking
into account that measuring tumour diameters is diﬃcult
and is based on the reliably of sequential imaging, one may
speculate that surveillance strategies should be limited to
patients with tumours below the diameter of 3cm.
To analyse which malignant potential small renal masses
might have, Gill et al. analyzed their own series. They
included tumours with a mean diameter of 2.8cm. Even
though it was assumed that the risk of malignancy was less
in smaller tumours, their ﬁndings showed that the majority
of these tumours were malignant with growth potential
[16, 18].
A l s o ,H s ue ta l .[ 25] showed that 38% of the 50 resected
RCCs of <3cm had extracapsular extension (pT3 or pT4)
and 28% were Fuhrman grade G3/G4.
Minardi et al. [26] considered 48 patients with pT1a
clear cell RCC. Of the patients treated with nephron-sparing
surgery, 3.9% died of metastatic renal cancer at a median
follow-up of 2 years, with one patient having Fuhrman grade
2 (G2), one having G3 and two having G4 RCCs.
These ﬁndings support resection of even small lesions
and support that recurrence and death are possible in
patients with small renal tumours even with low-grade RCC.
Active monitoring in these patients would have been unsafe.
W ec a nc o n c l u d et h a tn o ta l ls m a l lr e n a lt u m o u r sa r e
harmless and that even very small lesions may progress to
metastatic disease.
4. GROWTH RATE
4.1. Cantheinitialtumoursizepredictits
subsequentgrowthrate?
As stated above, one could not identify a signiﬁcant cor-
relation between initial tumour size and growth rate in an
analysis of 157 tumours from 5 observational series [5, 7–
9,13,16](P = .46). Therefore,the initial tumoursize cannot
predict the subsequent growth rate.
4.2. Growthornogrowth:whatcanitpredict?
When growth of (small) renal masses is apparent, it becomes
more likely that these lesions need treatment because
malignant behaviour is suspected. A recent meta-analysis
could conﬁrm this. The mean growth rate of pathologically
conﬁrmed RCC (92%) was signiﬁcantly greater than for
tumours continued under surveillance (0.40 ± 0.36 versus
0.21 ± 0.40cm per year, P = .0001). Also Kouba et al. [1]
showed a higher growth rate in patients undergoing eventual
intervention than for tumours continued under surveillance
(0.90 versus 0.61cm per year, resp.; P = .1486).
It remains however diﬃcult to predict biological
behaviour of small renal masses, even if they do not show
growth. We cannot conclude that small renal masses that
do not show growth during surveillance are less likely to be
cancerous.
Kunkle et al. [17] observed 106 renal masses for at least 1
year and compared clinical, radiographic, and pathological
characteristics of the lesions with zero or negative radio-
graphic growth (33%) versus those with positive growth
(67%) (median, 0.31cm per year). Rates of malignancy were
similar in both groups (83% and 89%, resp.; P = .56).
The results suggest that a lack of radiographic growth is not
associated with malignant potential or pathological ﬁndings.
In other observation series, Kouba et al. [1]. observed a
signiﬁcant diﬀerence in growth rates between grades 2 and 3
butnotbetweengrades1and2tumours.Growthratedidnot
c o rr el a t ewi t hp r o gn o s i s[ 16, 17]. In conclusion, the majority
of small renal masses grow and the majority are cancer. One
cannot safely assume that a lack of growth on serial CT
scanning conﬁrms the absence of malignancy. No clinical or
radiological predictors of growth rate are yet identiﬁed [17].
4.3. Whataboutageandgrowthrate?
A meta-analysis of published observation series [5, 6, 11–13,
16] demonstrated an inverse correlation between increasing
age and tumour growth rate. Also in the observation study
by Kouba et al. [1], patients ≤60 years (n = 15) had more
rapid growth rate of renal masses compared with those >60
years (n = 31) (0.90 versus 0.60, P = .0570). Because
youngerpatientshavelongerlifeexpectanciesandmostlikely
fewer comorbidities, these results provide greater support to
propose surgery in young patients with renal masses [1].
5. PROGRESSION TO METASTATIC DISEASE
There are no published reports of metastasis occurring in
the absence of tumour growth. While all observed lesions do
have the potential to metastasise, the risk to do so appears
low in the absence of growth. Yet follow-up is however short
a n dw eh a v et ot a k ei n t oa c c o u n tt h er e t r o s p e c t i v en a t u r eo f
these studies.
6. ROLE OF BIOPSY
The value of tumour biopsies remains controversial. Some
histologically proven RCCs may demonstrate nonaggressive4 Advances in Urology
Table 2: Tumour diameter and aggressiveness [24].
65 tumours: ≤2cm 103 tumours: 2.1–3.0cm 119 tumours: 3.1–4.0cm
73.8% RCC 78.6% RCC 82.4% RCC
24.6% benign 20.4% benign 16.0% benign
168 tumours: ≤3cm 119 tumours: 3.1–4.0cm
10.9% pT3a or greater 35.7% pT3a or greater
4.7% G3-G4 25.5% G3-G4
2.4% M+ 8.4% M+
behaviour, negative biopsy would not rule out RCC, and a
positive biopsy may signiﬁcantly understage or undergrade
the lesion [16, 27, 28]. Preoperative needle biopsies remain
inaccurate in 18 to 23% of patients [29, 30]. However, a
recent retrospective study of Vasudevan et al. [31] revealed
howeverthatahigherthanpreviouslyanticipatedproportion
of incidentally detected small renal masses are benign. Given
the high sensitivity and speciﬁcity of biopsies in their hands,
they proposed that there is value in taking a core biopsy of
small incidental renal lesions. The investigators concluded
that biopsy could avoid unnecessary surgery in one third
of the incidental renal masses. When using contemporary
biopsytechniques,theriskoftumourseedingorhemorrhage
is extremely low [32].
Although the accuracy of ﬁne-needle percutaneous
biopsy with CT guidance of small renal masses (<4cm)
evaluated in 88 patients was high for histopathological
tumour type (92%), biopsy was less accurate in evaluating
Fuhrman grade (70%) [33]. Many benign tumours may be
diagnosed with the help of biopsy ﬁndings, but more data
are still needed to understand the overall accuracy of biopsy
for the diagnosis of benign tumours [34].
We currently do not have any reliable molecular marker
for separating indolent from aggressive tumours [35]. How-
everarecentpilotstudy[36]demonstratedthatthedetection
of the MN/CA9 gene can reliably be detected in ﬁne-needle
aspiration biopsy and that this gene marker can be helpful in
separating malignant from benign renal tumours. It remains
to be conﬁrmed that other molecules such as carbonic
anhydrase IX and vascular endothelial growth factor could
potentially be used in conjunction with usual prognostic
parameters for reﬁning prognosis in small renal masses.
7. ACTIVE TREATMENT OPTIONS
In the majority of the patients, nephron-sparing surgery
remains the gold standard treatment because it is a safe and
eﬀective procedure and because even very small lesions may
progress to metastatic disease.
For frail patients who are not ﬁt for open or laparoscopic
nephron-sparing surgery, treatment option by minimally
invasive techniques, such as radiofrequency ablation and
cryoablation under ultrasound or CT guidance, might be
a middle way between aggressive treatment and expect
monitoring. These newer minimally invasive therapies have
become available for the treatment of small renal masses.
In patients who have medical comorbidities or a limited
life expectancy, radio frequency ablation and cryoablation
provides reasonable long-term oncological control and it
may have a role in the management of small renal masses
[37]. Meticulous long-term follow-up is however required in
patients receiving radio frequency ablation.
Cryoablation is less well investigated. Schwart et al.
[38] published is Urology in 2006 a retrospective analysis
of cryoablation of small peripheral renal masses. They
concluded that renal cryotherapy is a viable option for
nephron-sparing surgery in small, peripheral renal lesions.
The procedure has well-tolerated results, may be considered
in patients who are not good candidates for open surgical
approaches, in minimal morbidity, and has shown encour-
aging treatment results. Close post treatment surveillance
is essential. Meticulous long-term follow-up is however
required before these new ablative treatments can be consid-
ered a valuable alternative to surgical extirpation.
Furthermore, whether these treatments provide a beneﬁt
over surveillance strategies in older, poor surgical candidates
with limited life expectancy needs to be addressed in
prospective, randomised, clinical trials.
8. CONCLUSIONS
Approximately 26–33% of observed small renal masses
do not show radiographic growth. Therefore, it has been
suggested that a short period of active monitoring may be
feasible for a very selected patients group.
It has been proposed to delay treatment in these patients
when the tumour does not show growth. However, even
though tumour growth might be absent or slow, a pro-
portion of these tumours will express signiﬁcant malignant
behaviour, since the natural history and biological potential
of small renal masses can still not be unambiguously
predictedatpresent.Wethereforebelievethattheindications
for active surveillance with regular radiographic follow-up
are limited to elderly and/or inﬁrm patients with competing
health risks, to those with limited life expectancy and to poor
surgical candidates.
Inallotherpatients,activesurveillancecanbeconsidered
in the context of a study protocol only. It is noteworthy
that, because of the increase in life expectancy even in a
70-year-old otherwise healthy patient, some sort of active
treatment of small renal masses should be preferred over
surveillance [32]. Nephron-sparing surgery remains the
gold standard treatment of (small) renal masses. However,
minimally invasive techniques like radiofrequency ablationS. Klaver et al. 5
and cryoablation have emerged. While there is still a need
for prospective, randomised, clinical trials with suﬃcient
follow-up, these procedures are considered suitable for
patients who have limited life expectancy or are high-risk-
surgicalcandidates. These treatment strategies provide rea-
sonable short- and intermediate-term oncological control,
however long-term results are unavailable so far.
When facing patients with small bilateral or multiple
renal tumours, treatment strategies will not signiﬁcantly
diﬀer compared to patients with small single lesions, since
the indications for active surveillance remain limited to
elderly and/or inﬁrm patients with competing health risks
and those with limited life expectancy.
The value of tumour biopsies remains controversial.
Preoperative needle biopsy remains inaccurate in 18 to 23%
of patients. Molecular or biochemical markers as well as
better imaging techniques are required to select individuals
at the highest risk for tumour progression.
Todate,thereisnoanonstandardisedfollow-upprotocol
for surveillance. There is the patients’ fear of harbouring a
tumour with an uncertain malignant potential. Surveillance
requires a high degree of individual compliance by the
patient. Even in compliant patients there is a risk that
the onset of progression will be missed. When small renal
masses have progressed to metastatic disease, there are no
eﬀective systemic therapies available. The safety of longer-
term surveillance is still questionable. On the basis of current
literature, we have no data on the risk and cost of patients on
active surveillance.
Finally, the treatment modality of active monitoring
should always be combined with close follow-up imaging
and should be allowed only when the patient and the
urologist accept the calculated risk. Long-term, prospective
studies are needed to provide a more accurate assessment
of the natural history and metastatic potential of small
renal masses in the long term. Until long-term follow-up
resultsincludingoutcome,risk,andcostofpatientsmanaged
expectantly are available, no deﬁnitive guidelines can be
established for the surveillance of small renal masses.
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